12/3/2013 9:22:09 AM
Swedish Orphan Biovitrum AB's (publ ) (Sobi) partner Biogen Idec today announced
that new data from their haemophilia clinical development and research programs
will be presented at the 55th Annual Meeting of the American Society of
Hematology (ASH), taking place in New Orleans, December 7-10. Researchers will
discuss 10 abstracts covering the breadth of the company's comprehensive basic
and clinical research programs. This includes new interim data from Phase 3
studies in paediatric populations evaluating the company's investigational long-
lasting recombinant factor VIII Fc fusion protein candidate for haemophilia A
and factor IX Fc fusion protein candidate for haemophilia B.
Help employers find you! Check out all the jobs and post your resume.
comments powered by